|
|
Volumn 11, Issue 7, 2012, Pages 508-
|
|
Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
AZACITIDINE;
EPZ 004777;
HISTONE METHYLTRANSFERASE;
MIXED LINEAGE LEUKEMIA PROTEIN;
ROMIDEPSIN;
S ADENOSYLMETHIONINE;
UNCLASSIFIED DRUG;
ACUTE LEUKEMIA;
ANTIPROLIFERATIVE ACTIVITY;
DRUG APPROVAL;
DRUG CLASSIFICATION;
DRUG CYTOTOXICITY;
DRUG EFFECT;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG PROGRAM;
DRUG SCREENING;
DRUG TARGETING;
ECONOMIC EVALUATION;
EPIGENETICS;
EVIDENCE BASED MEDICINE;
FOOD AND DRUG ADMINISTRATION;
GENE REARRANGEMENT;
GENE TRANSLOCATION;
HISTONE METHYLATION;
HUMAN;
MLL GENE;
NONHUMAN;
NOTE;
ONCOGENE;
PRIORITY JOURNAL;
PROGRAM DEVELOPMENT;
ANIMALS;
DRUG DISCOVERY;
DRUG INDUSTRY;
ENZYME INHIBITORS;
EPIGENOMICS;
GENE THERAPY;
HISTONE-LYSINE N-METHYLTRANSFERASE;
HUMANS;
|
|
EID: 84863189520
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3772 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
